SCHEMBL18550583

SCHEMBL18550583

Fc1c(C(F)(F)F)nc(C(F)(F)F)nc1C(F)(F)F

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 1/20 0.33
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21306245 0.77
SCHEMBL175478 0.73 ALDH1A1 (0.33) RAB9A
SCHEMBL15358255 0.72 MEN1 (0.36)
SCHEMBL15358254 0.69 MEN1 (0.34)
SCHEMBL24228127 0.69 KDM5B (0.32) KDM5B
SCHEMBL10703268 0.69
SCHEMBL25164034 0.69 HTT (0.34) KDM5B
SCHEMBL21306206 0.69
SCHEMBL24228124 0.69 KDM5B (0.32) KDM5B
SCHEMBL12788225 0.69 KDM5B (0.32) KDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230247896-A1 Compound of Formula (I), a Semiconductor Material Comprising at Least One Compound of Formula (I), a Semiconductor Layer Comprising at Least One Compound of Formula (I) and an Electronic Device Comprising at Least One Compound of Formula (I) NOVALED GMBH (DE) 2023-08-03 US disclosed
US-20230247896-A1 Compound of Formula (I), a Semiconductor Material Comprising at Least One Compound of Formula (I), a Semiconductor Layer Comprising at Least One Compound of Formula (I) and an Electronic Device Comprising at Least One Compound of Formula (I) NOVALED GMBH (DE) 2023-08-03 US disclosed
US-20230247896-A1 Compound of Formula (I), a Semiconductor Material Comprising at Least One Compound of Formula (I), a Semiconductor Layer Comprising at Least One Compound of Formula (I) and an Electronic Device Comprising at Least One Compound of Formula (I) NOVALED GMBH (DE) 2023-08-03 US disclosed
EP-4188909-A1 METAL COMPLEXES OF 3-(2,3,5-TRIFLUORO-6-(TRIFLUOROMETHYL)PYRIDIN-4-YL)PENTANE-2,4-DIONE AND SIMILAR LIGANDS AS SEMICONDUCTOR MATERIALS FOR USE IN ELECTRONIC DEVICES Novaled GmbH (DE) 2023-06-07 EP disclosed
CN-116234796-A Metal complexes of 3- (2, 3, 5-trifluoro-6- (trifluoromethyl) pyridin-4-yl) pentane-2, 4-dione and similar ligands as semiconductor materials for electronic devices 诺瓦尔德股份有限公司 2023-06-06 CN disclosed
WO-2022023260-A1 METAL COMPLEXES OF 3-(2,3,5-TRIFLUORO-6-(TRIFLUOROMETHYL)PYRIDIN-4-YL)PENTANE-2,4-DIONE AND SIMILAR LIGANDS AS SEMICONDUCTOR MATERIALS FOR USE IN ELECTRONIC DEVICES NOVALED GMBH (DE) 2022-02-03 WO disclosed
US-20170050934-A1 ETHERIC (ETHEREAL) OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR ITS PRODUCTION ASAHI GLASS COMPANY, LIMITED (JP) 2017-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050934-A1 ETHERIC (ETHEREAL) OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR ITS PRODUCTION CYP2B6, PFAS, CYP2F1 KDM5B 1285/4885RAB9A 2948/4885
US-20230247896-A1 Compound of Formula (I), a Semiconductor Material Comprising at Least One Compound of Formula (I), a Semiconductor Layer Comprising at Least One Compound of Formula (I) and an Electronic Device Comprising at Least One Compound of Formula (I) C5, AFF2, SCO2 KDM5B 1439/4885RAB9A 3506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.